Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
9°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alpine Immune Sciences Inc
(NQ:
ALPN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alpine Immune Sciences Inc
< Previous
1
2
3
4
5
6
7
Next >
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 25, 2024
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via
Benzinga
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
January 25, 2024
U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Beyond The Numbers: 7 Analysts Discuss Alpine Immune Sciences Stock
December 22, 2023
Via
Benzinga
The Latest Analyst Ratings for Alpine Immune Sciences
November 15, 2023
Via
Benzinga
Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
December 22, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
December 21, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
What 8 Analyst Ratings Have To Say About Alpine Immune Sciences
October 18, 2023
Via
Benzinga
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
November 20, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
November 15, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
November 14, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
November 13, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 07, 2023
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Via
Benzinga
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 07, 2023
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
November 06, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Proposed Public Offering
November 06, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
November 03, 2023
The Benzinga Stock Whisper Index uses proprietary data to look at stocks with increased interest from investors.
Via
Benzinga
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
November 03, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Apple, Coinbase Global, Fortinet And Other Big Stocks Moving Lower In Friday's Pre-Market Session
November 03, 2023
U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 02, 2023
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 02, 2023
Via
Benzinga
Why Is Alpine Immune Sciences Stock Trading Higher Today?
November 02, 2023
Alpine Immune Sciences Inc (NASDAQ: ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology
Via
Benzinga
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
November 02, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
November 02, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
October 30, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
October 18, 2023
Via
Benzinga
Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
October 13, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
IgAN Treatment Market Worth Over $6B By 2032: Analyst Bearish On Povetacicept's Promising Role
October 05, 2023
RBC Capital Markets initiated coverage on Alpine Immune Sciences Inc (NASDAQ: ALPN), noting that the autoimmune disease market (over $165 billion) is meaningful for the company's lead candidate -...
Via
Benzinga
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
October 04, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
October 05, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.